Cogent Biosciences, Inc. (COGT)
36.19
-0.13
(-0.36%)
USD |
NASDAQ |
Apr 16, 16:00
36.18
-0.01
(-0.03%)
After-Hours: 20:00
Cogent Biosciences Research and Development Expense (Quarterly) : 74.38M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Syndax Pharmaceuticals, Inc. | 78.64M |
| Vera Therapeutics, Inc. | 59.18M |
| Terns Pharmaceuticals, Inc. | 18.90M |
| Nuvalent, Inc. | 67.80M |
| Insmed, Inc. | 254.91M |